Regeneron Pharmaceuticals (NASDAQ:REGN) Given “Overweight” Rating at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a report published on Thursday morning,Benzinga reports. Cantor Fitzgerald currently has a $800.00 price objective on the biopharmaceutical company’s stock.

Several other equities analysts have also recently commented on REGN. Bank of America raised shares of Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and increased their price target for the stock from $627.00 to $860.00 in a research report on Wednesday, January 7th. Piper Sandler started coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, March 31st. They set an “overweight” rating and a $875.00 price target on the stock. Morgan Stanley increased their price target on shares of Regeneron Pharmaceuticals from $769.00 to $796.00 and gave the stock an “equal weight” rating in a research report on Friday, April 10th. Oppenheimer reissued an “outperform” rating and issued a $865.00 target price (up from $750.00) on shares of Regeneron Pharmaceuticals in a report on Monday, February 2nd. Finally, Evercore raised their target price on shares of Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an “outperform” rating in a report on Thursday, January 22nd. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $818.13.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $766.02 on Thursday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.39 and a current ratio of 4.13. Regeneron Pharmaceuticals has a one year low of $476.49 and a one year high of $821.11. The company’s 50-day simple moving average is $763.87 and its 200-day simple moving average is $729.93. The stock has a market capitalization of $80.98 billion, a price-to-earnings ratio of 18.43, a PEG ratio of 1.66 and a beta of 0.40.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, topping the consensus estimate of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The business had revenue of $3.88 billion for the quarter, compared to analysts’ expectations of $3.76 billion. During the same quarter last year, the company posted $12.07 earnings per share. The company’s quarterly revenue was up 2.5% compared to the same quarter last year. Equities analysts anticipate that Regeneron Pharmaceuticals will post 35.2 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 5th. Shareholders of record on Friday, February 20th were issued a $0.94 dividend. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date of this dividend was Friday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is 9.05%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, SVP Jason Pitofsky sold 2,036 shares of the firm’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $778.52, for a total value of $1,585,066.72. Following the sale, the senior vice president owned 4,272 shares in the company, valued at approximately $3,325,837.44. This trade represents a 32.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Huda Y. Zoghbi sold 1,638 shares of the firm’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the completion of the sale, the director owned 1,703 shares in the company, valued at $1,330,604.99. The trade was a 49.03% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 3,774 shares of company stock worth $2,942,738. 7.02% of the stock is owned by company insiders.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Several large investors have recently made changes to their positions in REGN. Norges Bank acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at approximately $1,012,296,000. Price T Rowe Associates Inc. MD increased its stake in shares of Regeneron Pharmaceuticals by 142.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,949,797 shares of the biopharmaceutical company’s stock valued at $1,504,991,000 after purchasing an additional 1,144,887 shares during the period. Nuveen LLC increased its stake in shares of Regeneron Pharmaceuticals by 71.1% in the fourth quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company’s stock valued at $1,551,858,000 after purchasing an additional 835,240 shares during the period. Dodge & Cox increased its stake in shares of Regeneron Pharmaceuticals by 18.9% in the third quarter. Dodge & Cox now owns 4,550,845 shares of the biopharmaceutical company’s stock valued at $2,558,804,000 after purchasing an additional 724,562 shares during the period. Finally, Wellington Management Group LLP increased its stake in shares of Regeneron Pharmaceuticals by 8,620.0% in the fourth quarter. Wellington Management Group LLP now owns 664,465 shares of the biopharmaceutical company’s stock valued at $512,881,000 after purchasing an additional 656,845 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: FDA approves Otarmeni, the first gene therapy to restore hearing — a clear pipeline win that validates Regeneron’s genetic‑medicine platform and de‑risks future revenue streams tied to novel products. Read More.
• Positive Sentiment: Regulatory and clinical data look strong — trial results cited high responder rates (e.g., CHORD trial outcomes reported), supporting commercial potential and positive sentiment around commercialization prospects. Read More.
• Positive Sentiment: Company secured tariff relief under the White House agreement (three years) — a near‑term margin/cost benefit that investors view favorably. Read More.
• Positive Sentiment: Analyst support/upgrades — TD Cowen raised its price target (to $960) and Cantor Fitzgerald reaffirmed “overweight,” reinforcing buy-side conviction and likely contributing to demand. Read More.
• Positive Sentiment: Dupixent label expansions (U.S./EU pediatric approvals) add incremental, low‑risk revenue upside and diversify near‑term growth drivers beyond gene therapy. Read More.
• Neutral Sentiment: Regeneron will provide Otarmeni for free to eligible U.S. patients — a major PR/ access move that increases goodwill and access but reduces near‑term product revenue in the U.S.; it may help uptake and market positioning internationally. Read More.
• Negative Sentiment: The agreement includes offering prescriptions at “most‑favored‑nation” prices for some Americans — this could compress pricing and long‑run revenue/margins if broadly applied. Read More.
• Negative Sentiment: Sector weakness: broader health‑care stocks were lower in afternoon trading, which can cap upside even with company‑specific news. Read More.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.